Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...

Employer Direct Healthcare, a company that connects members with specialty care, has rebranded as Lantern and is expanding ...

Have current runners of Nigeria, led by a Yoruba, with their prodigal handling of the Nigerian economy and society, not ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase ...

The TRIM21 therapies have been shown to remove toxic tau proteins and reduce symptoms of neurodegeneration in mice.

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...